Signup Crypto ETF Stocks News

Coinbase Takes 50% Share of Circle's Residual USDC Reserve Revenue: Filing

Coinbase receives half the revenue from Circle's USDC reserves, deepening ties between the crypto giants, a new IPO filing reveals.

Source: decrypt.co
April 01, 2025 | 23:04:13
Category: News

Trump's 'Liberation Day' Creates 'Major Uncertainty' For Big Tech, Analyst Dan Ives Says - NVIDIA ( NASDAQ:NVDA )

Retaliatory measures from China could disrupt production of critical components of Nvidia's chips. Decreased consumer confidence and spending could weigh further on companies such as Tesla and Apple. The 'Trade of the Day' is now live. Get a high-probability setup with clear entry and exit ...

Source: www.benzinga.com
April 01, 2025 | 23:06:21
Category: News

MPWR Deadline in 6 Days: Kessler Topaz Meltzer & Check, LLP Reminds Monolithic Power Systems, Inc. ( MPWR ) Investors of Filing Deadline in Class Action Lawsuit - Monolithic Power Systems ( NASDAQ:MPWR )

RADNOR, Pa., April 01, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Washington against Monolithic Power ...

Source: www.benzinga.com
April 01, 2025 | 23:09:00
Category: News

Rocket Lab USA, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 28, 2025 Deadline to file Lead Plaintiff Motion - Rocket Lab USA ( NASDAQ:RKLB )

Investors can contact the law firm at no cost to learn more about recovering their losses

Source: www.benzinga.com
April 01, 2025 | 23:10:36
Category: News

$100 Invested In Old Republic Intl 5 Years Ago Would Be Worth This Much Today - Old Republic Intl ( NYSE:ORI )

Old Republic Intl ORI has outperformed the market over the past 5 years by 5.46% on an annualized basis producing an average annual return of 21.65%. Currently, Old Republic Intl has a market capitalization of $9.79 billion.

Source: www.benzinga.com
April 01, 2025 | 23:15:19
Category: News

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

TORONTO, ONTARIO, April 01, 2025 ( GLOBE NEWSWIRE ) -- COSCIENS Biopharma Inc. ( NASDAQ: CSCI ) ( TSX: CSCI ) ( "COSCIENS" or the "Company" ) , a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today ...

Source: www.globenewswire.com
April 01, 2025 | 23:25:00
Category: News

Volatus Aerospace to Present at the AI & Technology Virtual Investor Conference on April 3rd - Volatus Aerospace ( OTC:TAKOF )

TORONTO, April 01, 2025 ( GLOBE NEWSWIRE ) -- Volatus Aerospace Inc. TAKOF FLT ABB, a leader in innovative aerial solutions, invites individual and institutional investors, as well as analysts and advisors, to join the AI & Technology Virtual Investor Conference hosted by ...

Source: www.benzinga.com
April 01, 2025 | 21:00:00
Category: News

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Daix ( France ) , New York City ( New York, United States ) , April 1, 2025 - Inventiva ( Euronext Paris and Nasdaq: IVA ) ( "Inventiva" or the "Company" ) , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic ...

Source: www.globenewswire.com
April 01, 2025 | 21:00:00
Category: News

Highland Global Allocation Fund Declares Monthly Distributions of $0.088 Per Share - Highland Glb Allocation ( NYSE:HGLB )

DALLAS, April 1, 2025 /PRNewswire/ -- Highland Global Allocation Fund HGLB ( "the "Fund" ) today announced the declaration of monthly distributions of $0.088 per share, payable on the dates noted below.

Source: www.benzinga.com
April 01, 2025 | 21:00:00
Category: News

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis - Inventiva ( NASDAQ:IVA )

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval

Source: www.benzinga.com
April 01, 2025 | 21:00:00
Category: News

© Natavest 2025 - 2026